266 related articles for article (PubMed ID: 36120577)
1. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
[No Abstract] [Full Text] [Related]
2. Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.
Wang H; Cai H; Li L
Heliyon; 2024 Jan; 10(1):e23204. PubMed ID: 38163150
[TBL] [Abstract][Full Text] [Related]
3. Systematic Analyses of the Role of the Reader Protein of
Shao XY; Dong J; Zhang H; Wu YS; Zheng L
Front Mol Biosci; 2020; 7():577460. PubMed ID: 33344502
[TBL] [Abstract][Full Text] [Related]
4. N6-methyladenosine methylation-related genes
Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 negatively correlates with tumor immune infiltration in small cell lung cancer.
Chen G; Ren D; Wang Y; Wang H; Zhang J; Yang S
J Mol Histol; 2023 Aug; 54(4):365-377. PubMed ID: 37357252
[TBL] [Abstract][Full Text] [Related]
6. The biological function of m6A reader YTHDF2 and its role in human disease.
Wang JY; Lu AQ
Cancer Cell Int; 2021 Feb; 21(1):109. PubMed ID: 33593354
[TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
10. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
11. m
Chen X; Zhou X; Wang X
Exp Hematol Oncol; 2022 Apr; 11(1):21. PubMed ID: 35382893
[TBL] [Abstract][Full Text] [Related]
12. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
Tsuchiya K; Yoshimura K; Inoue Y; Iwashita Y; Yamada H; Kawase A; Watanabe T; Tanahashi M; Ogawa H; Funai K; Shinmura K; Suda T; Sugimura H
Oncoimmunology; 2021; 10(1):1962656. PubMed ID: 34408926
[TBL] [Abstract][Full Text] [Related]
13. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
14. YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.
Su G; Liu T; Han X; Sun H; Che W; Hu K; Xiao J; Li Y; Liu Y; Li W; Mei H
Front Pharmacol; 2021; 12():709548. PubMed ID: 34512342
[TBL] [Abstract][Full Text] [Related]
15. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
Ning Y; Li Y; Wang H
Front Genet; 2023; 14():1108167. PubMed ID: 36713082
[No Abstract] [Full Text] [Related]
16. Pan-Cancer Analysis Based on
Zhang Y; Wang S; Han S; Feng Y
Front Oncol; 2022; 12():844794. PubMed ID: 35359375
[TBL] [Abstract][Full Text] [Related]
17. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
18. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
19. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
[TBL] [Abstract][Full Text] [Related]
20. Potential impact of WTAP and YTHDF2 on tumor immunity in lung adenocarcinoma.
Zhang X; Cai X
Medicine (Baltimore); 2022 Nov; 101(45):e31195. PubMed ID: 36397411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
